AMENDMENT NO. 1 TO AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • October 29th, 2015 • Tandem Diabetes Care Inc • Surgical & medical instruments & apparatus
THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (“Amendment No. 1”) is made and entered into effective as of September 24, 2015 (the “Effective Date”), by and between Tandem Diabetes Care, Inc., a Delaware corporation, having a principal place of business at 11045 Roselle St., San Diego, CA 92121 (“Tandem”) and DexCom, Inc., a Delaware corporation, having a principal place of business at 6340 Sequence Drive, San Diego, CA 92121 (“DexCom”). Capitalized terms used herein and not otherwise defined shall have the same meanings as given them in the Agreement (as defined below).
AMENDED & RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • October 29th, 2015 • Tandem Diabetes Care Inc • Surgical & medical instruments & apparatus • Delaware
This Amended and Restated Development and Commercialization Agreement (this “AR Agreement”) is made and entered into on January 4, 2013 (the “Effective Date”) by and between Tandem Diabetes Care, Inc., a Delaware corporation, having a principal place of business at 11045 Roselle Street, Suite 200 San Diego, California 92121 (“Tandem”) and DexCom, Inc., a Delaware corporation, having a principal place of business at 6340 Sequence Drive, San Diego, CA 92121 (“DexCom”). This AR Agreement amends and restates in its entirety that certain Development and Commercialization Agreement dated February 1, 2012 by and between DexCom and Tandem (the "Original Agreement").
